Literature DB >> 14523288

The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India.

Nagalingeswaran Kumarasamy1, Suniti Solomon, Sreekanth K Chaguturu, Anish P Mahajan, Timothy P Flanigan, P Balakrishnan, Kenneth H Mayer.   

Abstract

We investigated the safety, tolerability and effectiveness of locally produced generic highly active antiretroviral therapy (HAART) regimens with a chart review conducted at YRG CARE, a tertiary HIV referral centre in India. A total of 333 patients had been on Indian-manufactured generic HAART for at least 3 months. In this cohort, generic HAART was safe, well tolerated and effective at increasing CD4 T-lymphocyte counts in patients with advanced HIV, comparable to the experience with proprietary HAART.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14523288     DOI： 10.1097/00002030-200310170-00019

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  15 in total

1.  AIDS in India.

Authors:  S Solomon; S S Solomon; A K Ganesh
Journal:  Postgrad Med J       Date:  2006-09       Impact factor: 2.401

2.  Evaluation of antiretroviral therapy results in Blantyre, Malawi.

Authors:  J J van Oosterhout; N Bodasing; J J Kumwenda; C Nyirenda; J Mallewa; P R Cleary; M P de Baar; R Schuurman; D M Burger; E E Zijlstra
Journal:  Malawi Med J       Date:  2005-12       Impact factor: 0.875

Review 3.  Tuberculosis and HIV co-infection: a practical therapeutic approach.

Authors:  Ronan A M Breen; Leonie Swaden; Jayne Ballinger; Marc C I Lipman
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.

Authors:  Amanda H Corbett; Mina C Hosseinipour; Jean Nyirenda; Cecelia Kanyama; Naser L Rezk; Pax Mkupani; Dorothy Sichali; Hsiao Tien; Angela Dm Kashuba; Charles Mwansambo; Ralf Weigel; Peter Kazembe
Journal:  Antivir Ther       Date:  2010

5.  Antiretroviral treatment roll-out in a resource-constrained setting: capitalizing on nursing resources in Botswana.

Authors:  K Miles; D J Clutterbuck; O Seitio; M Sebego; A Riley
Journal:  Bull World Health Organ       Date:  2007-07       Impact factor: 9.408

Review 6.  Financial burden of health services for people with HIV/AIDS in India.

Authors:  N Kumarasamy; K K Venkatesh; K H Mayer; Kenneth Freedberg
Journal:  Indian J Med Res       Date:  2007-12       Impact factor: 2.375

7.  Expansion of HIV-1 screening and anti-retroviral treatment programs in a resource-poor setting: results from a faith-based organization in Jos, Plateau State, Nigeria.

Authors:  Hillary Lum; Christian Isichei; Mercy Isichei-Wakili; Robert Redfield
Journal:  Afr Health Sci       Date:  2007-06       Impact factor: 0.927

8.  High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia.

Authors:  Laurent Ferradini; Vara Ouk; Olivier Segeral; Janin Nouhin; Anne Dulioust; Chanroeurn Hak; Isabelle Fournier; Nathalie Lerolle; Sopheak Ngin; Chhi Vun Mean; Jean-François Delfraissy; Eric Nerrienet
Journal:  J Int AIDS Soc       Date:  2011-03-26       Impact factor: 5.396

9.  The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment.

Authors:  Sanjeev Sinha; Sahajal Dhooria; Sanjiv Kumar; Nipam Shah; T Velpandian; Ak Ravi; Narendra Kumar; Hafeez Ahmad; Akshat Bhargwa; Karan Chug; Naresh Bumma; Rahul Chandrashekhar; Meera Ekka; Vishnu Sreenivas; Surendra K Sharma; Jc Samantaray; Ronald Mitsuyasu
Journal:  AIDS Res Ther       Date:  2011-11-02       Impact factor: 2.250

10.  The potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South Africa.

Authors:  Karen Schneider; Chidi Nwizu; Richard Kaplan; Jonathan Anderson; David P Wilson; Sean Emery; David A Cooper; Mark A Boyd
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.